Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' IDLE JR' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 79 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Corchero, J; Granvil, CP; Akiyama, TE; Hayhurst, GP; Pimprale, S; Feigenbaum, L; Idle, JR; Gonzalez, FJ
      The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4 alpha on the disposition of debrisoquine in the mouse

      MOLECULAR PHARMACOLOGY
    2. Chatton, JY; Idle, JR; Vagbo, CB; Magistretti, PJ
      Insights into the mechanisms of ifosfamide encephalopathy: Drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    3. Grevle, L; Guzey, C; Hadidi, H; Brennersted, R; Idle, JR; Aasly, J
      Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease

      MOVEMENT DISORDERS
    4. Idle, JR
      The heart of psychotropic drug therapy

      LANCET
    5. Idle, JR; Corchero, J; Gonzalez, FJ
      Medical implications of HGP's sequence of chromosome 22

      LANCET
    6. Idle, JR
      CYP2A6 polymorphism, nicotine, and environmental nitrosamines

      LANCET
    7. Kupfer, A; Idle, JR
      Methylene blue and fatal encephalopathy from ackee fruit poisoning

      LANCET
    8. London, SJ; Idle, JR; Daly, AK; Coetzee, GA
      Genetic variation of CYP2A6, smoking, and risk of cancer

      LANCET
    9. Leathart, JBS; London, SJ; Steward, A; Adams, JD; Idle, JR; Daly, AK
      CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles

      PHARMACOGENETICS
    10. LONDON SJ; IDLE JR; DALY AK; NAVIDI WC
      RE - LONDON,S.J. ET-AL (1997) - GENETIC-POLYMORPHISM OF CYP2D6 AND LUNG-CANCER RISK IN AFRICAN-AMERICANS AND CAUCASIANS IN LOS-ANGELES-COUNTY - CARCINOGENESIS, 18,1203-1214 - REPLY

      Carcinogenesis
    11. HADIDI H; IRSHAID Y; VAGBO CB; BRUNSVIK A; CHOLERTON S; ZAHLSEN K; IDLE JR
      VARIABILITY OF COUMARIN 7-HYDROXYLATION AND 3-HYDROXYLATION IN A JORDANIAN POPULATION IS SUGGESTIVE OF A FUNCTIONAL POLYMORPHISM IN CYTOCHROME-P450 CYP2A6

      European Journal of Clinical Pharmacology
    12. WALDUM HL; SANDVIK AK; IDLE JR
      GASTRIN IS THE MOST IMPORTANT FACTOR IN ECL TUMORIGENESIS

      Gastroenterology
    13. LONDON SJ; SULLIVANKLOSE T; DALY AK; IDLE JR
      LUNG-CANCER RISK IN RELATION TO THE CYP2C9 GENETIC-POLYMORPHISM AMONGCAUCASIANS IN LOS-ANGELES-COUNTY

      Pharmacogenetics
    14. BOUSTEAD C; TABER H; IDLE JR; CHOLERTON S
      CYP2D6 GENOTYPE AND SMOKING-BEHAVIOR IN CIGARETTE SMOKERS

      Pharmacogenetics
    15. LOVLIE R; DALY AK; IDLE JR; STEEN VM
      CHARACTERIZATION OF THE 16-KB AND 30+9-KB CYP2D6-XBAI-HAPLOTYPES(9)

      Pharmacogenetics
    16. LOVLIE R; DALY AK; IDLE JR; STEEN VM
      CHARACTERIZATION OF THE 16-KB AND 30+9-KB CYP2D6-XBAI-HAPLOTYPES(9)

      Pharmacogenetics
    17. FERNANDEZSALGUERO PM; SAPONE A; WEI XX; HOLT JR; JONES S; IDLE JR; GONZALEZ FJ
      LACK OF CORRELATION BETWEEN PHENOTYPE AND GENOTYPE FOR THE POLYMORPHICALLY EXPRESSED DIHYDROPYRIMIDINE DEHYDROGENASE IN A FAMILY OF PAKISTANI ORIGIN

      Pharmacogenetics
    18. FERNANDEZSALGUERO PM; SAPONE A; WEI XX; HOLT JR; JONES S; IDLE JR; GONZALEZ FJ
      LACK OF CORRELATION BETWEEN PHENOTYPE AND GENOTYPE FOR THE POLYMORPHICALLY EXPRESSED DIHYDROPYRIMIDINE DEHYDROGENASE IN A FAMILY OF PAKISTANI ORIGIN

      Pharmacogenetics
    19. HADIDI H; ZAHLSEN K; IDLE JR; CHOLERTON S
      A SINGLE AMINO-ACID SUBSTITUTION (LEU160HIS) IN CYTOCHROME-P450 CYP2A6 CAUSES SWITCHING FROM 7-HYDROXYLATION TO 3-HYDROXYLATION OF COUMARIN

      Food and chemical toxicology
    20. LONDON SJ; DALY AK; LEATHART JBS; NAVIDI WC; CARPENTER CC; IDLE JR
      GENETIC-POLYMORPHISM OF CYP2D6 AND LUNG-CANCER RISK IN AFRICAN-AMERICANS AND CAUCASIANS IN LOS-ANGELES-COUNTY

      Carcinogenesis
    21. ARMSTRONG M; DALY AK; BLENNERHASSETT R; FERRIER N; IDLE JR
      ANTIPSYCHOTIC DRUG-INDUCED MOVEMENT-DISORDERS IN SCHIZOPHRENICS IN RELATION TO CYP2D6 GENOTYPE

      British Journal of Psychiatry
    22. HILDESHEIM A; ANDERSON LM; CHEN CJ; CHENG YJ; BRINTON LA; DALY AK; REED CD; CHEN IH; CAPORASO NE; HSU MM; CHEN JY; IDLE JR; HOOVER RN; YANG CS; CHHABRA SK
      CYP2E1 GENETIC POLYMORPHISMS AND RISK OF NASOPHARYNGEAL CARCINOMA IN TAIWAN

      Journal of the National Cancer Institute
    23. MONKMAN SC; ELLIS JS; CHOLERTON S; THOMASON JM; SEYMOUR RA; IDLE JR
      AUTOMATED GAS-CHROMATOGRAPHIC ASSAY FOR AMLODIPINE IN PLASMA AND GINGIVAL CREVICULAR FLUID

      Journal of chromatography B. Biomedical applications
    24. LONDON SJ; DALY AK; LEATHART JBS; NAVIDI WC; IDLE JR
      LUNG-CANCER RISK IN RELATION TO THE CYP2C9-ASTERISK-1 CYP2C9-ASTERISK-2 GENETIC-POLYMORPHISM AMONG AFRICAN-AMERICANS AND CAUCASIANS IN LOS-ANGELES-COUNTY, CALIFORNIA/

      Pharmacogenetics
    25. DALY AK; FAIRBROTHER KS; ANDREASSEN OA; LONDON SJ; IDLE JR; STEEN VM
      CHARACTERIZATION AND PCR-BASED DETECTION OF 2 DIFFERENT HYBRID CYP2D7P CYP2D6 ALLELES ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPES/

      Pharmacogenetics
    26. DALY AK; BROCKMOLLER J; BROLY F; EICHELBAUM M; EVANS WE; GONZALEZ FJ; HUANG JD; IDLE JR; INGELMANSUNDBERG M; ISHIZAKI T; JACQZAIGRAIN E; MEYER UA; NEBERT DW; STEEN VM; WOLF CR; ZANGER UM
      NOMENCLATURE FOR HUMAN CYP2D6 ALLELES

      Pharmacogenetics
    27. CHOLERTON S; BOUSTEAD C; TABER H; ARPANAHI A; IDLE JR
      CYP2D6 GENOTYPES IN CIGARETTE SMOKERS AND NON-TOBACCO USERS

      Pharmacogenetics
    28. LONDON SJ; DALY AK; COOPER J; CARPENTER CL; NAVIDI WC; DING L; IDLE JR
      LUNG-CANCER RISK IN RELATION TO THE CYP2E1 RSA-I GENETIC-POLYMORPHISMAMONG AFRICAN-AMERICANS AND CAUCASIANS IN LOS-ANGELES-COUNTY

      Pharmacogenetics
    29. BODDY AV; ENGLISH M; PEARSON ADJ; IDLE JR; SKINNER R
      IFOSFAMIDE NEPHROTOXICITY - LIMITED INFLUENCE OF METABOLISM AND MODE OF ADMINISTRATION DURING REPEATED THERAPY IN PEDIATRICS

      European journal of cancer
    30. BODDY AV; YULE SM; WYLLIE R; PRICE L; PEARSON ADJ; IDLE JR
      INTRASUBJECT VARIATION IN CHILDREN OF IFOSFAMIDE PHARMACOKINETICS ANDMETABOLISM DURING REPEATED ADMINISTRATION

      Cancer chemotherapy and pharmacology
    31. YULE SM; BODDY AV; COLE M; PRICE L; WYLLIE R; TASSO MJ; PEARSON ADJ; IDLE JR
      CYCLOPHOSPHAMIDE PHARMACOKINETICS IN CHILDREN

      British journal of clinical pharmacology
    32. SANDY MS; ARMSTRONG M; TANNER CM; DALY AK; DIMONTE DA; LANGSTON JW; IDLE JR
      CYP2D6 ALLELIC FREQUENCIES IN YOUNG-ONSET PARKINSONS-DISEASE

      Neurology
    33. LOVLIE R; DALY AK; MOLVEN A; IDLE JR; STEEN VM
      ULTRARAPID METABOLIZERS OF DEBRISOQUINE - CHARACTERIZATION AND PCR-BASED DETECTION OF ALLELES WITH DUPLICATION OF THE CYP2D6 GENE

      FEBS letters
    34. BEYELER C; ARMSTRONG M; BIRD HA; IDLE JR; DALY AK
      RELATIONSHIP BETWEEN GENOTYPE FOR THE CYTOCHROME-P450 CYP2D6 AND SUSCEPTIBILITY TO ANKYLOSING-SPONDYLITIS AND RHEUMATOID-ARTHRITIS

      Annals of the Rheumatic Diseases
    35. HILDESHEIM A; CHEN CJ; CAPORASO NE; CHENG YJ; HOOVER RN; HSU MM; LEVINE PH; CHEN IH; CHEN JY; YANG CS; DALY AK; IDLE JR
      CYTOCHROME P4502E1 GENETIC POLYMORPHISMS AND RISK OF NASOPHARYNGEAL CARCINOMA - RESULTS FROM A CASE-CONTROL STUDY CONDUCTED IN TAIWAN

      Cancer epidemiology, biomarkers & prevention
    36. IDLE JR; SMITH RL
      PHARMACOGENETICS IN THE NEW PATTERNS OF HEALTH-CARE-DELIVERY

      Pharmacogenetics
    37. FURUYA H; FERNANDEZSALGUERO P; GREGORY W; TABER H; STEWARD A; GONZALEZ FJ; IDLE JR
      GENETIC-POLYMORPHISM OF CYP2C9 AND ITS EFFECT ON WARFARIN MAINTENANCEDOSE REQUIREMENT IN PATIENTS UNDERGOING ANTICOAGULATION THERAPY

      Pharmacogenetics
    38. STEEN VM; ANDREASSEN OA; DALY AK; TEFRE T; BORRESEN AL; IDLE JR; GULBRANDSEN AK
      DETECTION OF THE POOR METABOLIZER-ASSOCIATED CYP2D6(D) GENE DELETION ALLELE BY LONG-PCR TECHNOLOGY

      Pharmacogenetics
    39. CRESPI CL; STEIMEL DT; PENMAN BW; KORZEKWA KR; FERNANDEZSALGUERO P; BUTERS JTM; GELBOIN HV; GONZALEZ FJ; IDLE JR; DALY AK
      COMPARISON OF SUBSTRATE METABOLISM BY WILD-TYPE CYP2D6 PROTEIN AND A VARIANT CONTAINING METHIONINE, NOT VALINE, AT POSITION-374

      Pharmacogenetics
    40. BODDY AV; YULE SM; WYLLIE R; PRICE L; PEARSON ADJ; IDLE JR
      COMPARISON OF CONTINUOUS-INFUSION AND BOLUS ADMINISTRATION OF IFOSFAMIDE IN CHILDREN

      European journal of cancer
    41. BODDY AV; PROCTOR M; SIMMONDS D; LIND MJ; IDLE JR
      PHARMACOKINETICS, METABOLISM AND CLINICAL EFFECT OF IFOSFAMIDE IN BREAST-CANCER PATIENTS

      European journal of cancer
    42. BODDY AV; COLE M; PEARSON ADJ; IDLE JR
      THE KINETICS OF THE AUTOINDUCTION OF IFOSFAMIDE METABOLISM DURING CONTINUOUS-INFUSION

      Cancer chemotherapy and pharmacology
    43. DALY AK; LEATHART JBS; LONDON SJ; IDLE JR
      AN INACTIVE CYTOCHROME-P450 CYP2D6 ALLELE CONTAINING A DELETION AND ABASE SUBSTITUTION

      Human genetics
    44. HADIDI HF; CHOLERTON S; ATKINSON S; IRSHAID YM; RAWASHDEH NM; IDLE JR
      THE N-OXIDATION OF TRIMETHYLAMINE IN A JORDANIAN POPULATION

      British journal of clinical pharmacology
    45. DEBERKER D; IBBOTSON S; SIMPSON NB; MATTHEWS JNS; IDLE JR; REES JL
      REDUCED EXPERIMENTAL CONTACT SENSITIVITY IN SQUAMOUS-CELL BUT NOT BASAL-CELL CARCINOMAS OF SKIN

      Lancet
    46. THOMASON JM; SEYMOUR RA; ELLIS JS; KELLY PJ; PARRY G; DARK J; IDLE JR
      IATROGENIC GINGIVAL OVERGROWTH IN CARDIAC TRANSPLANTATION

      Journal of periodontology
    47. ELLIS JS; SEYMOUR RA; THOMASSON JM; BUTLER TJ; IDLE JR
      PERIODONTAL VARIABLES AFFECTING NIFEDIPINE SEQUESTRATION IN GINGIVAL CREVICULAR FLUID

      Journal of Periodontal Research
    48. HADIDI HF; IRSHAID YM; WOOSLEY RL; IDLE JR; FLOCKHART DA
      S-MEPHENYTOIN HYDROXYLATION PHENOTYPES IN A JORDANIAN POPULATION

      Clinical pharmacology and therapeutics
    49. YULE SM; BODDY AV; COLE M; PRICE L; WYLLIE R; TASSO MJ; PEARSON ADJ; IDLE JR
      CYCLOPHOSPHAMIDE METABOLISM IN CHILDREN

      Cancer research
    50. LONDON SJ; DALY AK; FAIRBROTHER KS; HOLMES C; CARPENTER CL; NAVIDI WC; IDLE JR
      LUNG-CANCER RISK IN AFRICAN-AMERICANS IN RELATION TO A RACE-SPECIFIC CYP1A1 POLYMORPHISM

      Cancer research
    51. FERNANDEZSALGUERO P; HOFFMAN SMG; CHOLERTON S; MOHRENWEISER H; RAUNIO H; RAUTIO A; PELKONEN O; HUANG JD; EVANS WE; IDLE JR; GONZALEZ FJ
      A GENETIC-POLYMORPHISM IN COUMARIN 7-HYDROXYLATION - SEQUENCE OF THE HUMAN CYP2A GENES AND IDENTIFICATION OF VARIANT CYP2A6 ALLELES

      American journal of human genetics
    52. LONDON SJ; DALY AK; COOPER J; NAVIDI WC; CARPENTER CL; IDLE JR
      POLYMORPHISM OF GLUTATHIONE-S-TRANSFERASE M1 AND LUNG-CANCER RISK AMONG AFRICAN-AMERICANS AND CAUCASIANS IN LOS-ANGELES-COUNTY, CALIFORNIA

      Journal of the National Cancer Institute
    53. GREGORY WL; DALY AK; DUNN AN; CAVANAGH G; IDLE JR; JAMES OFW; BASSENDINE MF
      ANALYSIS OF HLA-CLASS-II-ENCODED ANTIGEN-PROCESSING GENES TAP1 AND TAP2 IN PRIMARY BILIARY-CIRRHOSIS

      Quarterly Journal of Medicine
    54. CAPORASO N; WHITEHOUSE J; MONKMAN S; BOUSTEAD C; ISSAQ H; FOX S; MORSE MA; IDLE JR; CHUNG FL
      IN-VITRO BUT NOT IN-VIVO INHIBITION OF CYP2D6 BY PHENETHYL ISOTHIOCYANATE (PEITC), A CONSTITUENT OF WATERCRESS

      Pharmacogenetics
    55. HADIDI HF; CHOLERTON S; MONKMAN SC; ARMSTRONG M; IRSHAID YM; RAWASHDEH NM; DALY AK; IDLE JR
      DEBRISOQUINE 4-HYDROXYLATION (CYP2D6) POLYMORPHISM IN JORDANIANS

      Pharmacogenetics
    56. TEFRE T; DALY AK; ARMSTRONG M; LEATHART JBS; IDLE JR; BROGGER A; BORRESEN AL
      GENOTYPING OF THE CYP2D6 GENE IN NORWEGIAN LUNG-CANCER PATIENTS AND CONTROLS

      Pharmacogenetics
    57. ARMSTRONG M; FAIRBROTHER K; IDLE JR; DALY AK
      THE CYTOCHROME-P450 CYP2D6 ALLELIC VARIANT CYP2D6J AND RELATED POLYMORPHISMS IN A EUROPEAN POPULATION

      Pharmacogenetics
    58. LONDON SJ; DALY AK; THOMAS DC; CAPORASO NE; IDLE JR
      METHODOLOGICAL ISSUES IN THE INTERPRETATION OF STUDIES OF THE CYP2D6 GENOTYPE IN RELATION TO LUNG-CANCER RISK

      Pharmacogenetics
    59. YULE SM; WALKER D; PEARSON ADJ; IDLE JR
      POTENTIAL INHIBITION OF ALKYLATING AGENT METABOLISM BY FLUCONAZOLE

      European journal of clinical microbiology & infectious diseases
    60. BEYELER C; DALY AK; ARMSTRONG M; ASTBURY C; BIRD HA; IDLE JR
      PHENOTYPE GENOTYPE RELATIONSHIPS FOR THE CYTOCHROME-P450 ENZYME CYP2D6 IN RHEUMATOID-ARTHRITIS - INFLUENCE OF DRUG-THERAPY AND DISEASE-ACTIVITY/

      Journal of rheumatology
    61. GONZALEZ FJ; IDLE JR
      PHARMACOGENETIC PHENOTYPING AND GENOTYPING - PRESENT STATUS AND FUTURE POTENTIAL

      Clinical pharmacokinetics
    62. SEYMOUR RA; ELLIS JS; THOMASON JM; MONKMAN S; IDLE JR
      AMLODIPINE-INDUCED GINGIVAL OVERGROWTH

      Journal of clinical periodontology
    63. CHOLERTON S; ARPANAHI A; MCCRACKEN N; BOUSTEAD C; TABER H; JOHNSTONE E; LEATHART J; DALY AK; IDLE JR
      POOR METABOLIZERS OF NICOTINE AND CYP2D6 POLYMORPHISM

      Lancet
    64. DALY AK; CHOLERTON S; ARMSTRONG M; IDLE JR
      GENOTYPING FOR POLYMORPHISMS IN XENOBIOTIC METABOLISM AS A PREDICTOR OF DISEASE SUSCEPTIBILITY

      Environmental health perspectives
    65. GREGORY WL; GAME FL; FARRER M; IDLE JR; LAKER MF; JAMES OFW
      REDUCED SERUM LIPOPROTEIN(A) LEVELS IN PATIENTS WITH PRIMARY BILIARY-CIRRHOSIS

      Atherosclerosis
    66. WALKER D; FLINOIS JP; MONKMAN SC; BELOC C; BODDY AV; CHOLERTON S; DALY AK; LIND MJ; PEARSON ADJ; BEAUNE PH; IDLE JR
      IDENTIFICATION OF THE MAJOR HUMAN HEPATIC CYTOCHROME-P450 INVOLVED INACTIVATION AND N-DECHLOROETHYLATION OF IFOSFAMIDE

      Biochemical pharmacology
    67. GREGORY WL; JAMES OFW; TURNER I; MEESE CO; IDLE JR
      REEVALUATION OF THE METABOLISM OF CARBOCISTEINE IN A BRITISH WHITE-POPULATION

      Pharmacogenetics
    68. DALY AK; THOMAS DJ; COOPER J; PEARSON WR; NEAL DE; IDLE JR
      HOMOZYGOUS DELETION OF GENE FOR GLUTATHIONE S-TRANSFERASE-M1 IN BLADDER-CANCER

      BMJ. British medical journal
    69. ELLIS JS; MONKMAN SC; SEYMOUR RA; IDLE JR
      DETERMINATION OF NIFEDIPINE IN GINGIVAL CREVICULAR FLUID - A CAPILLARY GAS-CHROMATOGRAPHIC METHOD FOR NIFEDIPINE IN MICROLITER VOLUMES OF BIOLOGICAL FLUID

      Journal of chromatography. Biomedical applications
    70. ARMSTRONG M; IDLE JR; DALY AK
      A POLYMORPHIC CFOI SITE IN EXON-6 OF THE HUMAN CYTOCHROME-P450 CYP2D6GENE DETECTED BY THE POLYMERASE CHAIN-REACTION

      Human genetics
    71. BODDY AV; IDLE JR
      THE ROLE OF PHARMACOGENETICS IN CHEMOTHERAPY - MODULATION OF TUMOR RESPONSE AND HOST TOXICITY

      Cancer surveys
    72. DALY AK; CHOLERTON S; GREGORY W; IDLE JR
      METABOLIC POLYMORPHISMS

      Pharmacology & therapeutics
    73. ELLIS JS; SEYMOUR RA; THOMASON JM; MONKMAN SC; IDLE JR
      GINGIVAL SEQUESTRATION OF AMLODIPINE AND AMLODIPINE-INDUCED GINGIVAL OVERGROWTH

      Lancet
    74. IDLE JR; DALY AK
      NEW OPPORTUNITIES IN CANCER RISK-EVALUATION USING PCR-BASED DNA ANALYSIS FOR CYP2D6

      Environmental health perspectives
    75. GREGORY WL; MEHAL W; DUNN AN; CAVANAGH G; CHAPMAN R; FLEMING KA; DALY AK; IDLE JR; JAMES OFW; BASSENDINE MF
      PRIMARY BILIARY-CIRRHOSIS - CONTRIBUTION OF HLA CLASS-II ALLELE DR8

      Quarterly Journal of Medicine
    76. ELLIS JS; SEYMOUR RA; MONKMAN S; IDLE JR
      DISPOSITION OF NIFEDIPINE IN PLASMA AND GINGIVAL CREVICULAR FLUID IN RELATION TO DRUG-INDUCED GINGIVAL OVERGROWTH

      Journal of Periodontal Research
    77. FOSTER JR; IDLE JR; HARDWICK JP; BARS R; SCOTT P; BRAGANZA JM
      INDUCTION OF DRUG-METABOLIZING-ENZYMES IN HUMAN PANCREATIC-CANCER ANDCHRONIC-PANCREATITIS

      Journal of pathology
    78. BODDY AV; YULE SM; WYLLIE R; PRICE L; PEARSON ADJ; IDLE JR
      PHARMACOKINETICS AND METABOLISM OF IFOSFAMIDE ADMINISTERED AS A CONTINUOUS-INFUSION IN CHILDREN

      Cancer research
    79. YULE SM; PEARSON ADJ; BODDY AV; IDLE JR
      REPRODUCIBILITY OF METHODS RELATING TO CYCLOSPHOSPHAMIDE METABOLIC STUDIES - RESPONSE

      Journal of the National Cancer Institute


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/02/20 alle ore 20:59:47